Nevirapine Milpharm

Nevirapine, the active ingredient in Nevirapine Milpharm, is a non‑nucleoside reverse transcriptase inhibitor (NNRTI) presented as an oral tablet for oral administration. It inhibits HIV‑1 replication by targeting the reverse transcriptase enzyme and is indicated for use in adults and adolescents living with HIV‑1 infection.

GNH USA supplies Nevirapine Milpharm as a licensed, GDP‑compliant product sourced from the European Union, providing reliable access to hospitals, pharmacies and clinics worldwide. The company follows strict quality standards and supports international procurement processes.

Nevirapine is used in antiretroviral therapy to suppress HIV‑1 replication. It is part of combination regimens for the following conditions: - HIV‑1 infection (treatment‑naïve adults): reduces viral load and improves immune function. - HIV‑1 infection (treatment‑experienced adults): restores virologic control when resistance develops to other agents. - HIV‑1 infection (adolescents): provides effective viral suppression as part of pediatric ART protocols.

Nevirapine may cause a range of adverse reactions. Patients should be monitored for both common and serious events.

Common Side Effects: - Rash: mild skin eruption that may be itchy. - Nausea: feeling of stomach upset, sometimes with vomiting. - Fatigue: generalized tiredness affecting daily activities. - Headache: mild to moderate pain in the head region.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction with blistering and detachment. - Hepatic toxicity: elevated liver enzymes, hepatitis, or liver failure. - Severe hypersensitivity: fever, eosinophilia, and systemic symptoms requiring immediate discontinuation.

Nevirapine therapy requires careful monitoring and patient education. - Liver monitoring: perform baseline and periodic liver function tests. - Hepatitis B screening: test before initiating therapy to assess risk. - Hypersensitivity history: discontinue immediately if rash or systemic allergic reaction occurs. - Drug interactions: avoid co‑administration with strong CYP3A inducers. - Pregnancy and breastfeeding: assess risk–benefit; use only when clearly needed. - Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Nevirapine interacts with several medicines; clinicians should review patient regimens.

Major Interactions (Avoid): - Rifampicin: markedly reduces nevirapine plasma levels. - St. John’s wort: induces metabolism leading to subtherapeutic exposure. - Carbamazepine: strong CYP3A inducer that lowers nevirapine concentrations.

Moderate Interactions (Monitor Closely): - Efavirenz: may increase hepatotoxicity risk. - Zidovudine: combined use can enhance hematologic toxicity. - Methadone: nevirapine may reduce methadone levels, requiring dose adjustment.